The dollars and sense of drug-eluting stents

CMAJ. Canadian Medical Association Journal

Volumn 172, Issue 3, 2005, Pages 361-362

  Brophy, James M ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DRUG ELUTING STENT; HEALTH ECONOMICS; HIGH RISK PATIENT; NOTE; OUTCOMES RESEARCH; QUALITY ADJUSTED LIFE YEAR; RESTENOSIS; REVASCULARIZATION; RISK BENEFIT ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 13444301229     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1041486     Document Type: Note

References (13)

1. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-8.
2. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med 2003;138:777-86.
3. Shrive FM, Manns BJ, Galbraith PD, Knudtson ML, Ghali WA; for the APPROACH Investigators. Economic evaluation of sirolimus-eluting stents. CMAJ 2005;172(3):345-51.
4. Cohen DJ, Taira DA, Berezin R, Cox DA, Morice MC, Stone GW, et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the Stent Primary Angioplasty in Myocardial Infarction (stent-PAMI) trial. Circulation 2001;104(25):3039-45.
5. Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, et al; SIRIUS Investigators. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 2004;110(5):508-14.
6. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364:583-91.
7. Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004;110(10):1226-30.
8. Brophy J, Erickson L, for Agence d'Evaluation des Technologies et des Modes d'Interventions en Santé (AETMIS). An economic analysis of drug eluting coronary stents: a Québec perspective. Québec: AETMIS; 2004.
9. Greenberg D, Bakhai A, Neumann PJ, Cohen DJ. Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study. Health Policy 2004;70:207-16.
10. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364(9444):1519-21.
11. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004;109(6):701-5.
12. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med 1992;326:10-6.
13. Hueb W, Soares PR, Gersh BJ, Cesar LA, Luz PL, Puig LB, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol 2004;43(10):1743-51.